Guardant Health, Inc. · GH · Next earnings

Guardant Health, Inc. next earnings report

GH's next report date is not on the calendar yet. Here is where the last quarter left off and what remains open. Last quarter: Guardant Health raises 2026 outlook as Shield growth accelerates

Date not yet scheduled Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $-0.73 Analyst average (10 estimates)
Consensus revenue $369.3M Analyst average (13 estimates)
Report date TBD Not yet on the calendar
Session — Session not yet known

Where GH left off: FY2026 Q3

Full report

Guardant Health raises 2026 outlook as Shield growth accelerates

EPS surprise +61.3% Reported $-0.29 vs $-0.75
Revenue surprise +2.9% Reported $361.0M vs $350.7M
Stock move -9.0% Event window
Subsequent drift 0.0% Up to 20 sessions

Full-year 2026 revenue guidance increased to $1.36–$1.37 billion. The supplied analysis also cites a 65% non-GAAP gross-margin target; it does not provide a prior-quarter comparison for that target.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Shield volume growth may be affected by seasonality or may not be sustained.
  • Reimbursement and code-update timing could delay adoption of Guardant360 Liquid CDx; reimbursement pathways for Reveal Ultra and other MRD tests remain a concern.
  • Regulatory and review outcomes for Guardant360 Tissue PMA, ADLT designation and Reveal indications remain uncertain.
  • Competitive pressure from other liquid-biopsy and MRD providers could weigh on growth.

Questions analysts left open

  • Whether Shield growth is sustainable and how seasonality affects volume.
  • The contribution of the ESR1 companion diagnostic to overall revenue.
  • Timing of reimbursement for Reveal Ultra and other MRD tests, and progress on Guardant360 Tissue PMA and ADLT designation.

Ask FN2 about GH next report

Choose a question to continue your research
What should I watch for in GH's next earnings report?How did GH guide last quarter, and is consensus above or below that?Give me the bull and bear case going into GH earnings.

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Get the GH recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent GH quarters

All GH earnings
-9.0%FY2026 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.